Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biomed Pharmacother ; 133: 111012, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33254017

RESUMEN

The beneficial effects of prebiotic, such as fructo-oligosaccharides (FOS), in intestinal inflammation have been demonstrated in several studies. Herein, we evaluate whether joint treatment with FOS, both before and during mucositis, had additional beneficial effects and investigated the mechanisms underlying in the action of FOS on the intestinal barrier. BALB/c mice were randomly divided into five groups: CTR (without mucositis + saline solution), FOS (without mucositis + 6 % FOS), MUC (mucositis + saline solution), PT (mucositis + 6 % FOS supplementation before disease induction), and TT (mucositis + 6 % FOS supplementation before and during disease induction). Mucositis was induced by intraperitoneal injection (300 mg/kg) of 5-fluorouracil (5-FU). After 72 h, the animals were euthanized and intestinal permeability (IP), tight junction, bacterial translocation (BT), histology and morphometry, and immunoglobulin A secretory (sIgA), inflammatory infiltrate, and production of short-chain fatty acids (acetate, butyrate and propionate) were evaluated. The MUC group showed an increase in the IP, BT, and inflammatory infiltrate but a decrease in the tight junction expression and butyrate and propionate levels (P < 0.05). In the PT and TT groups, FOS supplementation maintained the IP, tight junction expression, and propionate concentration within physiologic levels, increased butyrate levels, and reduced BT and inflammatory infiltrate (P < 0.05). Total treatment with FOS (TT group) was more effective in maintaining histological score, morphometric parameters, and sIgA production. Thus, total treatment (prophylactic and therapeutic supplementation) with FOS was more effective than pretreatment alone, in reducing 5-FU-induced damage to the intestinal barrier.


Asunto(s)
Bacterias/efectos de los fármacos , Ácidos Grasos Volátiles/metabolismo , Microbioma Gastrointestinal/efectos de los fármacos , Íleon/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Mucositis/inducido químicamente , Oligosacáridos/farmacología , Prebióticos , Uniones Estrechas/efectos de los fármacos , Acetatos/metabolismo , Animales , Bacterias/metabolismo , Traslocación Bacteriana/efectos de los fármacos , Butiratos/metabolismo , Modelos Animales de Enfermedad , Fluorouracilo , Íleon/metabolismo , Íleon/microbiología , Íleon/patología , Inmunoglobulina A Secretora/metabolismo , Mediadores de Inflamación/metabolismo , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Mucosa Intestinal/patología , Masculino , Ratones Endogámicos BALB C , Mucositis/metabolismo , Mucositis/microbiología , Mucositis/patología , Permeabilidad , Propionatos/metabolismo , Uniones Estrechas/metabolismo , Uniones Estrechas/microbiología , Uniones Estrechas/patología
2.
J Nat Prod ; 82(11): 3010-3019, 2019 11 22.
Artículo en Inglés | MEDLINE | ID: mdl-31710486

RESUMEN

Myocardial infarction (MI) leads to high mortality, and pharmacological or percutaneous primary interventions do not significantly inhibit ischemia/reperfusion injuries, particularly those caused by oxidative stress. Recently, research groups have evaluated several naturally occurring antioxidant compounds for possible use as therapeutic alternatives to traditional treatments. Studies have demonstrated that d-limonene (DL), a monoterpene of citrus fruits, possesses antioxidant and cardiovascular properties. Thus, this work sought to elucidate the mechanisms of protection of DL in an isoproterenol-induced murine MI model. It was observed that DL (10 µmol) attenuated 40% of the ST elevation, reduced the infarct area, prevented histological alterations, abolished completely oxidative stress damage, restored superoxide dismutase activity, and suppressed pro-apoptotic enzymes. In conclusion, the present study demonstrated that DL produces cardioprotective effects from isoproterenol-induced myocardial infarction in Swiss mice through suppression of apoptosis.


Asunto(s)
Antioxidantes/uso terapéutico , Apoptosis/efectos de los fármacos , Limoneno/uso terapéutico , Infarto del Miocardio/tratamiento farmacológico , Especies Reactivas de Oxígeno/metabolismo , Animales , Proteínas Reguladoras de la Apoptosis/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/metabolismo , Electrocardiografía/efectos de los fármacos , Síndrome de QT Prolongado/prevención & control , Masculino , Ratones , Estructura Molecular , Estrés Oxidativo/efectos de los fármacos , Superóxido Dismutasa/metabolismo
3.
Biomed Pharmacother ; 103: 1567-1576, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29864944

RESUMEN

BACKGROUND: Studies have showed the protective effects of conjugated linoleic acid (CLA) on intestinal epithelium, modulating host immune and inflammatory responses on intestinal diseases. OBJECTIVE: To evaluate the preventive effects of CLA on the intestinal mucositis induced by 5-FU in a murine model. METHODS: Sixty-four BALB/c mice were randomly divided into four groups: Control (CTL), fed a standard chow diet; CLAs, fed a diet supplemented with CLA; Mucositis (5-FU), fed a standard chow diet and underwent mucositis induction and CLAs 5-FU, fed a diet supplemented with CLA and underwent mucositis induction. Mucositis was induced by intraperitoneal injection of 300 mg/kg 5-FU. After 72 h, the animals were euthanized and intestinal permeability, bacterial translocation, inflammatory mediators, and intestinal histology were evaluated. RESULTS: Mice in the CLAs 5-FU group showed reduced weight loss compared to those in the 5-FU group (p < 0.005). Furthermore, the results also showed that the treatment with CLA reduced intestinal permeability, bacterial translocation, and biomarkers of inflammatory response besides minor damage to ZO-1 and occludin with maintenance of the integrity of the intestinal epithelium and a favorable balance between the inflammatory and regulatory cytokines. CONCLUSION: This study suggests that CLA reduced the adverse effects from 5-FU administration on the intestinal mucosa.


Asunto(s)
Fluorouracilo/efectos adversos , Intestinos/patología , Ácidos Linoleicos Conjugados/uso terapéutico , Mucositis/tratamiento farmacológico , Mucositis/prevención & control , Animales , Traslocación Bacteriana/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Quimiocinas/metabolismo , Modelos Animales de Enfermedad , Conducta Alimentaria , Inmunoglobulina A/metabolismo , Inflamación/patología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/patología , Ácidos Linoleicos Conjugados/farmacología , Masculino , Ratones Endogámicos BALB C , Mucositis/microbiología , Mucositis/patología , Distribución Tisular/efectos de los fármacos
4.
J Ethnopharmacol ; 180: 114-23, 2016 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-26806570

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Sida pilosa Retz (Malvaceae) is a plant used in Africa for the treatment of intestinal helminthiasis, lower abdominal pains and dysmenorrhea. AIM OF THE STUDY: In order to determine the potential use of S. pilosa in the treatment of schistosomiasis mansoni, we evaluated the schistosomicidal, antioxidant and anti-fibrotic properties of the aqueous extract and the n-butanol fraction of its aerial parts. MATERIAL AND METHODS: S. pilosa aqueous extract (SpAE) at 100, 200 and 400mg/kg and n-butanol fraction (SpBF) at 50, 100 and 200mg/kg were administered per os to Schistosoma mansoni-infected mice for 4 weeks. Praziquantel (100mg/kg × 5 days) was used as reference drug. After sacrifice, worm burden and egg count, transaminases and proteins levels were evaluated. Malondialdehyde (MDA), lipid hydroperoxydes (LOOH), catalase (CAT), superoxide dismutase (SOD), eosinophil peroxidase (EPO) and myeloperoxidase (MPO) were also measured. The anti-fibrotic effect of the plant was evaluated by the determination of hydroxyproline and γ-interferon (IFN-γ). RESULTS: The treatment of S. mansoni-infected mice by SpAE or SpBF resulted in a moderate reduction of worm burden and egg load in the liver and intestine. Both SpAE and SpBF significantly reversed the increasing liver proteins, MDA, LOOH and CAT levels induced by the infection. Moreover, SOD activity was improved by SpAE and SpBF. Schistosomiasis mansoni considerably increased the EPO (p<0.001) and MPO activities (p<0.001). SpAE treatment significantly reduced EPO and MPO activities at all doses. SpBF failed to reduce the increasing MPO and decreased EPO only at the highest dose. S. mansoni-infection induced an increase in hydroxyproline content (p<0.001) and a decrease in IFN-γ level (p<0.001). Both SpAE and SpBF significantly reduced hepatic hydroxyproline content, while only SpAE (p<0.05) improved IFN-γ level. CONCLUSION: These results suggest that the liver pathology in schistosomiasis mansoni is improved by S. pilosa aqueous extract, which disclosed a moderate schistosomicidal, but strong antioxidant and anti-fibrotic activities. The n-butanol fraction was however less active than the aqueous extract.


Asunto(s)
Antihelmínticos/uso terapéutico , Antioxidantes/uso terapéutico , Cirrosis Hepática/tratamiento farmacológico , Malvaceae , Extractos Vegetales/uso terapéutico , Esquistosomiasis mansoni/tratamiento farmacológico , 1-Butanol/química , Animales , Antihelmínticos/farmacología , Antioxidantes/farmacología , Catalasa/metabolismo , Heces/parasitología , Femenino , Interferón gamma/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/parasitología , Hígado/patología , Cirrosis Hepática/metabolismo , Cirrosis Hepática/parasitología , Cirrosis Hepática/patología , Malondialdehído/metabolismo , Ratones , Fitoterapia , Componentes Aéreos de las Plantas , Extractos Vegetales/farmacología , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/metabolismo , Esquistosomiasis mansoni/parasitología , Esquistosomiasis mansoni/patología , Solventes/química , Superóxido Dismutasa/metabolismo , Agua/química
5.
JPEN J Parenter Enteral Nutr ; 40(3): 417-22, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25135690

RESUMEN

BACKGROUND: The purpose of this study was to assess the effect of arginine supplementation on arginase activity, tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) synthesis in cultured splenic macrophages from a murine model of intestinal obstruction (IO). The effects of nitric oxide synthase (iNOS) inhibition were also studied using iNOS knockout animals. MATERIAL AND METHODS: Male C57BL6/J wild-type (WT) and iNOS knockout (iNOS-/-) mice were randomized into 6 groups: Sham and Sham-/- (standard chow), IO and IO-/- (standard chow + IO), and Arg and Arg-/- (standard chow supplemented with arginine + IO). After 7 days of treatment with standard or supplemented chow, IO was induced. Arginase activity as well as TNF-α and IL-10 levels were analyzed in splenic macrophage cultures. RESULTS: Arginine supplementation and the absence of iNOS increased arginase activity in splenic macrophages (Arg, IO-/-, and Arg-/- groups vs the Sham group; P < .05). Arginine was also related to a decrease in TNF-α levels (Arg vs IO group, P < .05) and maintenance of IL-10 levels (Arg vs other groups, P > .05). The inhibition of iNOS did not result in effects on the concentration of cytokines (Sham-/-, IO-/-, and Arg-/- vs other, P < .05). CONCLUSIONS: Arginine supplementation and iNOS inhibition led to increased arginase activity. Arginine availability decreased plasma TNF-α levels, which may be directly related to nitric oxide derived from arginine.


Asunto(s)
Arginasa/metabolismo , Arginina/farmacología , Obstrucción Intestinal/tratamiento farmacológico , Macrófagos/efectos de los fármacos , Bazo/efectos de los fármacos , Factor de Necrosis Tumoral alfa/metabolismo , Animales , Suplementos Dietéticos , Interleucina-10/metabolismo , Macrófagos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/metabolismo , Bazo/citología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
6.
JPEN J Parenter Enteral Nutr ; 40(2): 279-86, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25573703

RESUMEN

BACKGROUND: Mucositis is a common complication in patients undergoing radiotherapy and chemotherapy. It is associated with pain, poor quality of life, and malnutrition, leading to an increased number of hospital admissions and prolonged hospitalization. The use of immunonutrients may be an alternative treatment option, which may help to improve patient outcome. OBJECTIVE: Here we assessed the impact of L-citrulline (CIT) on a murine model of 5-fluorouracil (5FU)-induced mucositis. METHODS: Swiss male mice were randomized into 4 groups: control, CIT, 5FU, and 5FU+CIT. Mice were fed with commercial chow and supplemented with an oral solution of alanine (control and 5FU groups) or CIT (CIT and 5FU+CIT groups). On the seventh day, mice received intraperitoneal phosphate-buffered saline or 5FU (200 mg/kg, single dose) to induce mucositis. On the 10th day, mice were euthanized, and the blood and small intestines were harvested. Body weight, morphology, histopathology score (hematoxylin and eosin) of the small intestine (from 0-12), myeloperoxidase activity, oxidative stress level, and intestinal permeability were assessed. RESULTS: We observed significant weight loss after the administration of 5FU in both treated and control animals. CIT administration contributed to a partial recovery of the mucosal architecture as well as an intermediate reduction of the histopathologic score, and functional intestinal permeability was partially rescued. CONCLUSIONS: CIT administration attenuated 5FU-mediated damage to the mucosal architecture of the small intestine, decreasing the size of the injured areas and promoting decreased intestinal permeability.


Asunto(s)
Citrulina/farmacología , Mucosa Intestinal/efectos de los fármacos , Mucositis/tratamiento farmacológico , Animales , Suplementos Dietéticos , Modelos Animales de Enfermedad , Fluorouracilo/efectos adversos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Masculino , Ratones , Mucositis/inducido químicamente , Estrés Oxidativo/efectos de los fármacos , Permeabilidad
7.
JPEN J Parenter Enteral Nutr ; 37(3): 392-400, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-22914893

RESUMEN

BACKGROUND: Arginine has been shown to have several immunological and trophic properties in stressful diseases. Its metabolites, nitric oxide (NO) and polyamines, are related to arginine's effects. Thus, the aim of this study was to determine the effects of the NO donor L-arginine and the role of inducible NO synthase (iNOS) on intestinal permeability and bacterial translocation in a model of intestinal obstruction (IO) induced by a simple knot in the terminal ileum. MATERIAL AND METHODS: Male C57BL6/J wild-type (WT) and iNOS knockout (iNOS-/-) mice were randomized into 6 groups: Sham and Sham-/- (standard chow), IO and IO-/- (standard chow +IO), and Arg and Arg-/- (standard chow supplemented with arginine + IO). After 7 days of treatment with standard or supplemented chows, IO was induced and intestinal permeability and bacterial translocation were evaluated. The small intestine and its contents were harvested for histopathological and morphometric analysis and the determination of polyamine concentration. RESULTS: Pretreatment with arginine maintained intestinal permeability (P > .05; Arg and Arg-/- groups vs Sham and Sham-/- groups), increased polyamine concentration in intestinal content (P < .05; Arg vs IO group), and decreased bacterial translocation in WT animals (Arg group vs IO and IO-/- groups). Absence of iNOS also presented a protective effect on permeability but not on bacterial translocation. CONCLUSION: Arginine supplementation and synthesis of NO by iNOS are important factors in decreasing bacterial translocation. However, when intestinal permeability was considered, NO had a detrimental role.


Asunto(s)
Arginina/administración & dosificación , Traslocación Bacteriana/efectos de los fármacos , Escherichia coli/fisiología , Intestino Delgado/metabolismo , Intestino Delgado/microbiología , Óxido Nítrico Sintasa de Tipo II/genética , Animales , Íleon/efectos de los fármacos , Íleon/metabolismo , Íleon/patología , Obstrucción Intestinal/metabolismo , Obstrucción Intestinal/microbiología , Obstrucción Intestinal/patología , Intestino Delgado/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Permeabilidad , Poliaminas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA